Edward Abrahams, Ph.D., is executive director of the Personalized Medicine Coalition (PMC). Representing a broad spectrum of academic, industrial, patient, provider and payer communities, PMC seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. It has grown from its original 18 founding members in November 2004 to over 160 today.

Previously Dr. Abrahams was Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.

Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for the House Committee on the Interior.

Mara is President and CEO of On-Q-ity Inc., an innovative personalized medicine company based in Waltham, Massachusetts. On-Q-ity: Oncology + Quality + Clarity. On-Q-ity revolutionizes cancer patient care by guiding individual treatment choices through proactive interventions. On-Q-ity enables clarity in the choice of patient of therapy and the real –time monitoring of therapy efficacy of an individual patients’ treatment, remission and potential relapse through the molecular characterization of circulating tumor cells in the blood.

For the last seven years, Mara was President of Genzyme Genetics, leading provider of testing in the oncology and reproductive markets. Under Mara's leadership, Genzyme Genetics set the standard for quality in the industry, while profitably growing at an unprecedented pace. She transformed the business – expanding its scope and reach to become one of the nation’s largest diagnostic laboratories. Previously, Mara served as President of Genzyme Pharmaceuticals where she restructured the business from generic drug manufacturing to value-added custom production. 

Mara has been on the Board of Predictive Biosciences since its inception, serving as Chairman for the last year.  Mara is also a Board member of Blue Cross Blue Shield of Massachusetts.

Mara has an appointment as Lecturer in Health Care Policy at Harvard Medical School and will teach a seminar on business and medicine each year.  

She is an active member of the Federal Secretary of Health and Human Services’ Advisory Commission on Genetics, Health and Society as well as Vice Chairman of the Personalized Medicine Coalition. Most recently, she co-authored, “Realizing the Promise of Personalized Medicine” in the Harvard Business Review. 

Bain & Company, an international strategic consulting firm, was where Mara started her business career. She earned her MBA from Harvard and her BA from Tufts University. 

Linda Avey is the founder of Brainstorm Research Foundation, a not-for-profit organization focused on the study of the genetics of brain health, specifically targeted toward families with a history of Alzheimer's disease.  By leveraging existing technology platforms and social networking tools, Brainstorm's mission is to create a global network of individuals and empower them with their genetic information combined with web-based mechanisms for longitudinal tracking of brain functions.  This is also a personal mission for Linda, whose father-in-law suffered with Alzheimer's.

In 2006, Linda founded 23andMe, the personal genetics company.  She and her co-founder, Anne Wojcicki, pioneered many of the concepts that led to the creation of a new consumer industry and the development of a DNA research and media platform.  The company won TIME magazine's Invention of the Year in 2008 and received international attention through featured articles in Wired, New York Times, Fortune, and on Oprah, the TODAY show and the BBC (additional coverage is listed here, www.23andme.com/about/news/).  While no longer acting in a day-to-day role, Linda supports the company's efforts.

Linda's career spans over 20 years in the biopharmaceutical and academic research industry. Her experiences at Affymetrix, Perlegen Sciences, Spotfire, Chemdex, Applied Biosystems and Molecular Dynamics provided an intensive view into the mechanisms of the traditional research model.  With that insight came the idea of creating a new, complementary and consumer-based approach that thrives today at 23andMe and is the motivation for Brainstorm.

Linda has a Bachelor of Arts in biology from Augustana College.

Alison Ayers is responsible for global strategic and commercial leadership for Pfizer’s oncology portfolio  including Sutent, a leading anti-angiogenesis agent as well as 20+ agents in clinical development and extensive lifecycle planning.  She is a member of the Oncology Business Unit Leadership Team which develops the Oncology TA Strategic Plan, and manages the portfolio including asset prioritization, development planning, strategic and investment decisions including licensing and acquisitions.  She is responsible for the global commercial strategy for Pfizer’s oncology portfolio, which had sales of over $2billion in 2008.

Previously positions include Vice President of New Product Marketing for Pharmacia Oncology, where she was responsible for providing commercial leadership for Pharmacia’s oncology pipeline, and served a pivotal role in the acquisition of Sugen, which delivered Pfizer’s leading angiogenesis inhibitor, Sutent.

Ayers received a B.S. with honors in physiology and biochemistry from the University of Southampton, UK.  She later received a diploma in business studies from North London University, UK, and went on to earn a M.S. with distinction in biopharmacy from London University, UK. 

G. Steven Burrill is Chief Executive Officer of Burrill & Company, a San Francisco based life sciences firm.  He has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Boards of Pharmasset (NASDAQ: VRUS), BioImagene and NewBridge, and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed (NASDAQ: DEPO), Ikano Therapeutics, Proteogenix, Proventys, Targacept (NASDAQ: TRGT) and XDx. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50), and in 2008, he received the BayBio Pantheon 2008 DiNA lifetime achievement award for his worldwide biotech leadership.

In addition to his work with leading life science companies, Mr. Burrill is a founder and currently serves as the Chairman of the Board of the Foundation for the National Medals of Science and Technology. Additionally, he serves as Chairman of the San Francisco Mayor’s Biotech Advisory Committee (MAYBAC). Other not-for-profit activities include serving on the Boards of Directors of the Bay Area Science Infrastructure Consortium, BayBio, California Healthcare Institute (Emeritus), The Exploratorium, The Kellogg Center for Biotechnology, the University of Maryland Biotechnology Institute, the MIT Center for Biomedical Innovation, Kramden Institute, and the National Health Museum. He also serves on the Purdue Discovery Park External Advisory Committee as well as the editorial board of the Journal of Commercial Biotechnology, is on the advisory board of the Center for Policy on Emerging Technologies (C-PET) and serves as an advisor to University of Illinois Institute for Genomic Biology, University of Wisconsin—College of Agriculture and Life Sciences, and Duke University, and is an adjunct professor at University of California, San Francisco.

Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than fifty new technology based ventures, over half of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 110 Life Sciences companies which have already developed hundreds of products to treat major underserved medical needs for millions of patients.

Brook was the founding President and then Chairman, of four biotechnology companies which were incubated in KPCB's offices and went on to become public companies with an aggregate market value over $8 Billion. He is currently on the Board of Directors of ten companies, most recently joining CardioDX, Genomic Health Incorporated, Five Prime Therapeutics, OptiMedica, Pacific Biosciences, Inc., Tethys and XDx, Inc. He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Onyx Pharmaceuticals, Hybritech (Chairman), Genprobe and others. These companies have pioneered the medical use of molecular biology, monoclonal antibodies, personalized medicine, molecular diagnostics and genomics.

Brook was President and a Director of the Western Association of Venture Capitalists. He is a currently a Board member of the University of California at San Francisco Medical Foundation, the New Schools Foundation, Stanford’s Bio-X Advisory Council and the Stanford Eye Council. He was Co-Chair of the five year, $1.4 billion, UCSF Capital Campaign. In 2007, he was awarded the “UCSF Medal” as their honorary degree equivalent. In 2008, he was elected a Fellow of the American Academy of Arts and Sciences. In 2009, he received the Lifetime Achievement Award from the National Venture Capital Association.

Raised in Atlanta, Georgia, Brook graduated in Electrical Engineering from Georgia Tech and received an MBA from Stanford.

Pierre Cassigneul is the CEO of XDx since 2003.  Prior to this he was a partner with the consulting firm, Stone Bridge. Formerly he was at Becton Dickinson. As Vice President Diabetes Management, he led the company's efforts in entering the blood glucose monitoring market. Pierre also worked at Bayer where he was Senior VP and General Manager of the Diabetes business unit, at Ortho  (J&J) where he was VP and GM of the AIDS and Hepatitis Business Unit, and at Abbott  where he held several US and European general management and marketing positions. Pierre has a management degree from the ESC Reims.

Brett Davis is a Senior Director in Oracle's Health Sciences Global Business Unit.  In this role, Brett is responsible for shaping and driving Oracle's personalized healthcare strategy and solutions.  He works closely with leaders in healthcare and life sciences to help them leverage innovative information technologies and applications to innovate and grow. 

Prior to joining Oracle, Brett was a Business Unit Executive in IBM's Healthcare and Life Sciences business.  In this role, he was involved in helping shape IBM’s strategy for health analytics, clinical genomics, high performance scientific computing, biobanking and translational medicine. 

In addition to his role at Oracle, he is on the Board of Directors of the Personalized Medicine Coalition, is on HRSA’s Genetic Services Policy Project Advisory Panel, is a Strategic Advisor for the Ben and Catherine Ivy Foundation for glioma research, and has been an invited speaker at industry meetings on information technology’s transformative role in the health sciences. 

Prior to joining IBM, Brett led business development and marketing efforts at Genstruct, Inc., a Cambridge, MA based biotech.  Previously he served as Senior Product Manager and Director of Marketing for Viaken Systems, Inc., where he helped develop and market bioinformatics and knowledge management solutions for pharmaceutical research. 

Brett is a graduate of The Pennsylvania State University where he was enrolled in the accelerated Science BS/MBA Program, and graduated as the Eberly College of Science Student Marshall.

Brett lives outside Philadelphia with his wife Virginia and two children, Owen and Emery.

Richard Ding has over 15 years of research and management experience in the pharmaceutical and diagnostics industry. As a member of the team at Myriad Genetics that cloned BRCA1 gene, he made significant contribution to the development of one of the first molecular genetic tests.  Prior to joining bioMerieux, he took various cross-functional positions at Eli Lilly and company.  In addition to his current role at bioMerieux as VP for Strategy and Business Development, Richard Ding serves as the CEO of bioTheranostics, a wholly-owned subsidiary of bioMerieux.  Richard Ding holds an MBA from the University of Utah and received his undergraduate education at Fudan University, China

John Fallon, M.D. is responsible for ensuring the highest standards of medical care for our members.  He is also accountable for helping expand health care strategies involving quality, effectiveness, efficiency and their relationships to new payment methodologies.  He oversees the company’s medical policies, acts as the main liaison with the plan’s provider network, reviews upcoming legislation for medical impact, manages the company’s medical directors, acts as primary spokesperson for medical inquires and main medical contact with the Blue Cross Blue Shield Association and its 39 plans.

John practiced Internal Medicine for over 20 years.  Additionally, he was previously CEO for the entire clinical enterprise at the State University of New York’s Downstate Medical Center.  His professional experience also includes the Partners HealthCare System, where he was Chairman of the physician network.  He was also the founder and CEO of North Shore Health System, a large physician-hospital organization in Massachusetts.

He serves on many boards; locally, among them are the Neighborhood Health Plan and the New England Healthcare Institute, nationally the NCQA Medical Standards, and Temple University School of Medicine Board of Advisors.  Currently is co-chair of the State of Massachusetts Patient Centered Medical Home Initiative Coordination Council.

John is Board Certified in Internal Medicine, a Clinical Professor in the Graduate Program of Public Health at SUNY Downstate Medical Center College of Medicine and is a Fellow of the American College of Physicians. 

Jon Friedenberg became a Vice President of El Camino Hospital in 2002. He has also played a leadership role in the creation of the South Asian Heart Center, The Fogarty Institute for Innovation and the Genomic Medicine Institute.  Jon received his Bachelor of Arts from the University of California, Berkeley and a Master of Arts from the University of California, Davis. Jon was also a Fellow with the California Healthcare Leadership College and the Wexner Heritage Foundation.

John Glaser, PhD, is Vice-President and Chief Information Officer, Partners HealthCare System, Inc. Previously, he was Vice-President, Information Systems at Brigham and Women’s Hospital. Prior to Brigham and Women's Hospital, Dr. Glaser managed the Healthcare Information Systems consulting practice at Arthur D. Little.

Dr. Glaser was the founding Chairman of College of Healthcare Information Management Executives (CHIME) and is past President of the Healthcare Information and Management Systems Society (HIMSS). He is past-President of the eHealth Initiative and has been a member of the Board of the American Medical Informatics Association.

Dr. Glaser is a former member of the Board of the National eHealth Collaborative. He is the former co-Chair of the Board of the National Alliance for Healthcare Information Technology. He has been a Senior Advisor to the Deloitte Center for Health Solutions and is a Senior Advisor, Office of the National Coordinator for Health Information Technology, HHS.

He is a fellow of HIMSS, CHIME and the American College of Medical Informatics. He has been awarded the John Gall award for healthcare CIO of the year. CHIME has established a scholarship in Dr. Glaser’s name. He was elected to CIO Magazine’s CIO Hall of Fame. Partners HealthCare has received several industry awards for its effective and innovative use of information technology.

Dr. Glaser has published over one hundred and fifty articles and three books on the strategic application of information technology in healthcare. He holds a Ph.D. in Healthcare Information Systems from the University of Minnesota.

Richard Hamermesh is the MBA Class of 1961 Professor of Management Practice at the Harvard Business School where he teaches in the MBA Program and is the Faculty Chair of the HBS Healthcare Initiative. Richard created and teaches the second-year MBA elective, Entrepreneurship and Venture Capital in Healthcare. Previously, he was the Course Head for the required first year course entitled The Entrepreneurial Manager.  In addition Richard participates in several HBS Executive Education programs.

From 1987 to 2001, Richard was a co-founder and a Managing Partner of The Center for Executive Development, an executive education and development consulting firm. Prior to this, from 1976 to 1987, he was a member of the faculty of the Harvard Business School.

Richard is also an active investor and entrepreneur, having participated as a principal, director, and investor in the founding and early stages of over 20 organizations. These have included start-ups, leveraged buy-outs, industry roll-ups, and non-profit foundations. He was the founding president of the Newton (MA) Schools Foundation and served on the editorial board of the Harvard Business Review. He is currently on the Boards of one public and two private corporations, as well as two non-profit Boards. From 1991 to 1996, he was the founding Chairman of Synthes Spine, Inc.

Richard is the author or co-author of five books, including New Business Ventures and the Entrepreneur. His best-known book, Fad-Free Management, was published in 1996. He has published numerous articles and more than 100 case studies. His most recent article, "Realizing the Potential of Personalized Medicine," appeared in the Harvard Business Review (October 2007).  Richard received his AB from the University of California, and his MBA and DBA from HBS. He is married, has two children, and his hobbies include tennis, skiing, and yoga.

Dr. Gerardo Jimenez-Sanchez was born in Mexico City. He obtained his Medical Doctor degree from the National Autonomous University of Mexico (UNAM). He did his residency in Pediatrics at the National Institute of Pediatrics and earned his Ph.D. Degree in Human Genetics and Molecular Biology from the Johns Hopkins University in Baltimore, MD, USA.

Dr. Jimenez-Sanchez is Professor of Genomic at the UNAM and Resident Investigator of the Mexican Health Foundation (FUNSALUD). He is also Director General of the National Institute of Genomic Medicine and affiliate member of the Institute of Genetic Medicine at Johns Hopkins University. His actual work focuses on the development of a national platform in genomic medicine for Mexico. This includes the conduction of major scientific research projects, including the production of the first haplotype map for the Mexican Mestizo population.

Dr. Jimenez-Sanchez is a certified pediatrician and a member of the Mexican Academy of Pediatrics, the National Academy of Medicine, the Mexican Society of Biochemistry and the American Societies of Human Genetics, Inborn Errors of Metabolism and Gene Therapy, the European Society of Inborn Errors of Metabolism and the Human Genome Organization

(HUGO).

Dr. Jimenez-Sanchez work has resulted in the publication of articles and chapters in specialized journals and books. He received the Research in Pediatrics Award of the Society for Pediatric Research in 1999. Along with his colleagues David Valle and Barton Childs, he did the first medical analysis of the human genome, published with the first draft of the human genome in 2001. He received the National Award in Clinical Investigation “Dr. Miguel Otero” from the Government of Mexico. In April of 2003, he was appointed Silanes Professor in Genomic Medicine. He is the regional editor for Latin America and the Carribean of the Journal Genomic Medicine and charter member of the international Public Population Project in Genomics (P3G Consortium).

Raju Kucherlapati came to the United States in 1967 after receiving his B.S. in Biology at  P.R. College, Kakinada, India and his M.S. in Biology at Andhra University, Waltair, India.  He received his Ph.D. from the University of Illinois at Urbana and did his post-doctoral work in the lab of Frank Ruddle at Yale University.  He was assistant professor in the Department of Biochemical Sciences at Princeton University, then became professor in the Department of Genetics at the University of Illinois College of Medicine. In 1989 Dr. Kucherlapati went to the Albert Einstein College of Medicine where he was the Lola and Saul Kramer Professor of Molecular Genetics and Chairman of the Department of Molecular Genetics, a position he held for eleven years.  In 2001 Dr. Kucherlapati became the Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School and was the first Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG).

At HPCGG Dr. Kucherlapati devoted his energies to advancing the cause of personalized medicine. Under his direction HPCGG launched initiatives that resulted in a large number of novel molecular diagnostics; built new information technology programs that captured the results of clinical and basic genetic research in structured formats that could then be applied meaningfully in clinical decision making that would benefit diagnosis, prognosis and treatment of patients. He also strengthened and developed new training and educational programs for physicians, scientists, healthcare professionals, patients, and others in human genetics and genomics and the application of genetics in healthcare. He stepped down as the Scientific Director of the Center in late 2008. He continues to promote personalized medicine in all of its facets at the national level.

Dr. Kucherlapati contributed to several different areas of research.  These include gene targeting and homologous recombination, human gene mapping, generation of physical maps of the human genome with special emphasis on human chromosome 12, development of techniques to modify genes in mammalian cells and in cloning many human disease genes.  To date he holds 12 patents. He was a member and Chair of several review committees at the NIH, was a member of the National Advisory Council for Human Genome Research at the National Human Genomics Research Institute, and was a co-chair of the steering committee for the National Cancer Institute’s Mouse Models for Human Cancer Consortium. He served on the editorial board of the New England Journal of Medicine and was editor in chief of the journal Genomics.  He is a fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences.

Dr. Kucherlapati was a founder of Cell Genesys, Abgenix and  Millennium Pharmaceuticals. He currently serves on the boards of privately held AVEO Pharmaceuticals and Enlight Biosciences. 

Nick Littlefield, Partner and Chair, Government Strategies Group, at Foley Hoag LLP, a full service law firm located in Boston, Massachusetts and Washington, DC, concentrates his practice on subjects including, scientific innovation, biomedical research and development, personalized medicine, and health care technology.  He specializes in regulatory, administrative, legislative and policy issues for large and small companies, non-profit organizations and trade associations.  Nick and his colleagues in the Foley Hoag Life Sciences Group work with clients on regulatory matters before federal and state agencies including, the Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA), as well as on legislative matters in the Congress.

For nine years until 1998, Nick served as Staff Director and Chief Counsel for the late Massachusetts Senator Edward M. Kennedy on the United States Senate Health, Education, Labor and Pensions Committee.  During Mr. Littlefield’s tenure with Senator Kennedy such legislative initiatives as, the Health Insurance Portability and Accountability Act (1996), the Children’s Health Insurance Program (“CHIP”) (1997), the National Institutes of Health Revitalization Act (1993), the Food & Drug Administration Modernization Act (1997), the Ryan White AIDS Care Act (1990), the Family and Medical Leave Act (1993), and American with Disabilities Act (1990), were enacted through the Committee.

Mr. Littlefield is a member of the board or advisory committee for a number of non-profit healthcare policy organizations, including the Blue Cross Blue Shield of Massachusetts Foundation, New England Healthcare Institute (Executive Committee and Chair, Policy Committee), Massachusetts General Hospital/Partners HealthCare System Institute for Health Policy (member of the Board of Advisors), Massachusetts Biotech Council (co-chair, Legal and Government Affairs Committee), and the Heller School of Social Policy, Brandeis (Board of Overseers).

Previously, Mr. Littlefield taught at Harvard Law School as the Edward Johnson Lecturer on Law from 1978 to 1989, and served as chief counsel to the Massachusetts Special Anti-Corruption Commission from 1978 to 1980 and as Assistant U.S. Attorney for the Southern District of New York from 1972-1976.  He received his AB from Harvard College and LLB from the University of Pennsylvania Law School.

return to top

Sheila D. Walcoff is a partner in the Washington DC office of the law firm of McDermott Will & Emery LLP and a member of the Firm’s Health Law Department and Life Sciences Government Strategies Practice Group.  Her clients include leading pharmaceutical and biotechnology companies, innovative diagnostic companies, policy associations and coalitions.

A recognized health policy expert, Ms. Walcoff focuses her practice on personalized medicine and related science and health policy, regulatory and legal matters.  Previously, Ms. Walcoff served as Counselor to the Secretary of the U.S. Department of Health and Human Services (HHS), Associate Commissioner for External Affairs at the Food and Drug Administration (FDA) and the health policy team leader/senior health policy advisor to a 2008 presidential campaign.  She also has significant legislative strategy and advocacy experience and served as the majority counsel to the U.S. House of Representatives Armed Services Committee.  Her ongoing pro bono work includes legislative and policy counsel to a national eating disorder association.  Ms. Walcoff serves on the HHS Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS) and the Massachusetts Institute of Technology (MIT) Center for Biomedical Innovation (CBI) Strategy and Policy Council; she was recently elected to the Board of the Friends of the National Zoo (FONZ).

Outside of her law firm practice Ms. Walcoff is an entrepreneur and co-owns several veterinary hospitals.  She earned her J.D. from the Georgetown University Law Center and resides in Maryland with her husband, Dr. Jeff Walcoff, their two young sons, and two Labradors.

return to top

Scott T. Weiss, M.D., M.S. is the Interim Director of Partners HealthCare Center for Personalized Genetic Medicine.  He serves as Director of the Center for Genomic Medicine (Department of Medicine, Brigham & Women’s Hospital) and Associate Director, Channing Laboratory, and Professor of Medicine at Harvard Medical School. In this capacity, he leads a 25 investigator, 110 person research group examining the environmental and genetic origins of asthma and COPD.

He has authored or coauthored over 500 publications and four books in the area of asthma and COPD risk factors, natural history, and genetics.  His initial work concerned the role of airways responsiveness and environmental tobacco smoke exposure in asthma and COPD, the effect of allergen exposure and airways responsiveness on markers of inflammation and the combined effect of these factors on the development of COPD.  In 1996, he developed a strong interest in the genetics of asthma and his recent work has focused on this, and novel environmental exposures such as vitamin D and the bowel flora. His laboratory is the only laboratory in the world that has active NIH research in the areas of asthma genetics, asthma pharmacogenetics, and COPD genetics. He is the principal investigator or co-investigator on a total of six separate NHLBI-funded grant proposals in the area of the genetics of asthma and Asthma Pharmacogenetics, including a MERIT award. 

Dr. Weiss has international research experience in China, The United Kingdom, Norway, Mexico, Costa Rica, and the Netherlands.  Dr. Weiss is Principal Investigator of a long standing T-32 Training grant (HL-07427).  Dr Weiss has had 27 trainees in the last 15 years, 25 of whom are still in academic medicine.  He has served in an administrative capacity with the NHLBI including the Special Emphasis Panel on the Use of NHLBI Specimens, the Oversight Committee for the Collaborative Study on the Genetics of Asthma,  the NHLBI Genotyping Service Study Section, the T-32 review study section, and the oversight committee for the NHLBI re-sequencing and genotyping facility.